The Trial Protocol Amendment Mid-Enrolment
A sponsor is running a multicentre trial of a new anticoagulant in patients over 65 with atrial fibrillation. The Bahrain site has enrolled 38 of a planned 60 participants. In June the sponsor learns from interim data that the risk of major bleeding is higher than expected in participants with a creatinine clearance below 30 mL/min. The sponsor drafts a protocol amendment excluding such patients and adding a monthly renal function test. The principal investigator at the Bahrain site wants to apply the amendment immediately to all 38 existing participants, stop their participation if renal function has declined, and enrol new participants under the revised criteria before the amendment is approved. He argues that acting quickly protects patients and that ethics approval is a formality since the change is safety-driven. The site's research governance officer asks for advice on the correct sequence and on what to do about the 38 already enrolled.
1. Explain the correct regulatory sequence for implementing the amendment, and evaluate the investigator's proposal to act before approval.
Read the worked answer
The proposal is partly right in motive and wrong in sequence. Safety-driven amendments still require approval before implementation, except where an immediate change is necessary to eliminate an apparent hazard to participants. Even then, the change must be reported promptly to the ethics committee and regulator, with the reason, and full approval sought afterwards.
Here, the hazard is known from interim data but is not an emergency affecting a participant right now. The correct sequence is: submit the substantial amendment to the ethics committee and the regulator; obtain approval; then implement. Enrolment of new participants under the revised criteria should pause until approval, because enrolling under unapproved criteria exposes participants and invalidates consent. The investigator should not unilaterally stop existing participants either; stopping a participant is itself a protocol deviation unless done under the approved amendment or for that individual's clinical safety.
However, the investigator retains a duty of care. If an individual participant's renal function has already fallen below 30 mL/min, the investigator should assess that participant clinically and, if continuing poses immediate risk, act in the participant's interest, document the deviation, and report it. That is an individual safety decision, not a wholesale protocol change.
The distinction matters: population-level protocol change requires approval; individual clinical judgement can override protocol where necessary to protect a participant, provided it is documented and reported.
2. Describe how the 38 enrolled participants should be managed once the amendment is approved, including consent and monitoring implications.
Read the worked answer
Once approved, the site should apply the amendment prospectively and review all 38 participants against the new renal criterion. Participants whose creatinine clearance is below 30 mL/min should be withdrawn from the investigational product under the approved amendment, with a documented withdrawal visit, safety assessment and follow-up plan. They should not simply be dropped; the protocol should specify follow-up for safety.
Consent requires attention. Adding a monthly renal function test changes the burden and risk information participants were given. Where the amendment materially affects participation, participants should be re-consented with the updated information sheet, and the ethics committee will usually require this. Participants who decline re-consent should be managed per the protocol's withdrawal provisions.
Monitoring implications include updating the data management plan, the case report forms for renal monitoring, and the site's delegation log if new tasks are assigned. The sponsor should also review whether the interim finding is a suspected unexpected serious adverse reaction requiring reporting, and whether other sites need the same amendment urgently. The site should document the date of approval, the date of implementation and the re-consent dates, because inspectors check that implementation followed approval rather than preceded it. The reasoning is that participant protection and valid consent drive the sequence, not administrative convenience.